A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma

BACKGROUND: There is no standard first-line therapy for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma and the prognosis remains poor. Our institution conducted a phase I study of oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule. The regimen was tolera...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Brell, Joanna M., Krishnamurthi, Smitha S., Javle, Milind, Saltzman, Joel, Wollner, Ira, Pelley, Robert, Dowlati, Afshin, Kantharaj, Belagodu N., Schluchter, Mark D., Rath, Linda, Ivy, S. Percy, Remick, Scot C.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209292/
https://ncbi.nlm.nih.gov/pubmed/18670776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0807-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares